NCT05068024 - A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

October 30, 2022

Study Completion Date

December 30, 2025

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

FWD1509 MsOH

FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.

Trial Locations (2)

44718

NOT_YET_RECRUITING

Gabrail Cancer Center, Canton

77030

RECRUITING

MD Anderson Cancer Center, Houston